Explosion’ of incretin therapy use among new developments in cardiology

2025-04-10 - 2025-04

“We’re able to finally talk about truly evidence-based therapies that allow us to change the natural history for heart failure with preserved ejection fraction,” he explained. “We’re able to review about 50 years of information that emphatically demonstrate the progress we’ve made in reducing the risk of death and disability due to heart failure by at least 50% over the last several decades.”
Yancy also talked about improved knowledge about risk modification for conditions like hypertension and the “continued explosion of the use of the incretin therapies in the cardiovascular space.”We’re completely engaged, yet we understand we have to navigate the cost of therapy and the equation that is the difference between cost and value,” he added.

The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma

2025-04-09 - 2025-04

Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing myocardial ischaemia (a mismatch between myocardial blood supply and demand). However, this model, which focuses on diagnosing and managing coronary artery disease based on ischaemia and cardiovascular events, is flawed. By the time ischaemia manifests, it is often too late for optimal intervention, limiting the effectiveness of treatment options. Despite decades of medical advances, coronary artery disease continues to be a leading cause of morbidity and mortality globally, highlighting the inadequacy of this traditional ischaemia-centric model.
The Lancet home. Opens in new tab
FREE with registration!

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

2025-04-04 - 2025-04

The cost of treatment has increased continuously over the last decade. However, the package rates have not increased accordingly, which is creating obstacles in providing quality treatment to patients, claim the cardiologist
The forum said, “The aim of PMJAY is to make healthcare accessible. But the rates decided by ignoring the economic realities are a hindrance. Insufficient increase in PCI (Percutaneous Coronary Intervention) and other packages is making it difficult to provide interventional cardiology services under PMJAY.”

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

2025-04-04 - 2025-04

Bayer Pharma to expand cardiology, women’s health portfolios with new drugs this year

2025-04-02 - 2025-04

Bayer on Tuesday announced that it was preparing market launches this year of two new drugs from its cardiology and women’s health portfolios reportedly to strengthen its pharmaceuticals business amid a high debt burden.

The company maintained tat it has made significant investments in R&D to accelerate medical innovations and build a highly differentiated pipeline for long-term growth across key therapeutic areas, including oncology, cardiovascular diseases, neurology and rare diseases, and immunology.

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

2025-04-02 - 2025-04

The Tell-Tale Heart podcast host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP, was on the ground in Chicago, Illinois, for the 2025 American College of Cardiology Scientific Session. Beavers spoke with several presenters, researchers, and experts about the key data being discussed at the meeting.
The first guest of this episode, Glen Harrington, PharmD, FACC, FHFSA, BCCP, CPP, HFCert, discussed what the ACC meeting has to offer, specifically for pharmacists in all areas of expertise. As co-chair of the Pharmacists’ Work Group at ACC, Harrington focuses on supporting pharmacists involved in cardiology.

Dr. Christopher Kramer is New American College of Cardiology President

2025-03-31 - 2025-03

"I see significant challenges and opportunities for the field of cardiology in the coming years, including workforce issues, health equity, diversity and inclusion, and AI-driven solutions, that need to be addressed to achieve ACC's mission of transforming cardiovascular care for all," Kramer said. "I am looking forward to using my term as president to help ACC be a leader on these issues, while getting to know more of our inspiring, diverse membership and hearing their concerns and achievements across the U.S. and throughout the world."

Kramer, whose interest in cardiology began during a summer scholarship program in high school, received his medical degree from the University of California, San Francisco School of Medicine. He completed his residency and chief residency in internal medicine and fellowship in cardiology at the Hospital of the University of Pennsylvania in Philadelphia. His first faculty appointment was at Allegheny General Hospital in Pittsburgh, then MCP/Hahnemann University School of Medicine in Philadelphia, where he directed the cardiology fellowship before moving in 1999 to the University of Virginia School of Medicine in Charlottesville, Virginia, where he became chief of

How 2 new Miami Tech endeavors aim ‘to bring the heartbeat back’

2025-03-31 - 2025-03

When Chris Daniels shared on Linkedin that he has joined The LAB Miami as General Manager and he is partnering with Erick Gavin to create and run a full-cycle entrepreneurship program called Reefside Ventures in Miami, he described it best: It’s a “full-circle moment” in his 10-year journey to help accelerate Miami’s rise as a global tech hub.

Daniels most recently helped create and run, with Gavin, the Built In Miami program as part of Venture Miami, and earlier founded and ran the Shrimp Society to engage founders and young professionals at the earliest stages. He also has worked at startups and dabbled in angel investing. It all started a decade ago in Daniels’ days as a “startup junkie” while studying at University Miami. He would spend evenings at tech events at The LAB Miami, one of Miami tech’s pioneers, to experience and be part of “the real startup world.”

GE HealthCare Introduces Measures to Improve Cardiac Care Pathway

2025-03-28 - 2025-03

GE HealthCare today announced the U.S. launch of its Flyrcado (flurpiridaz F 18) injection. The company made the announcement as it prepares to showcase new artificial intelligence (AI)-powered innovations at the 2025 American College of Cardiology (ACC) Annual Scientific Session and Expo (March 29-31), reflecting its strategy to leverage AI to help increase efficiency and enable seamless data integration across the cardiology care pathway.
GE HealthCare has been investing in AI for many years and has topped the U.S. Food and Drug Administration (FDA) list of AI-enabled device authorizations for three consecutive years with 85 authorizations.i

Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling

2025-03-27 - 2025-03

High circulating levels of ceramides, particularly long-chain ceramides, are an independent risk factor for atherosclerotic cardiovascular disease, but the mechanisms by which circulating ceramides might drive atherosclerosis development and progression are not well understood. A study published in Nature has identified two transmembrane G protein-coupled receptors (GPCRs) that mediate extracellular-to-intracellular ceramide signalling and shows that this signalling axis triggers activation of the NLRP3 inflammasome in endothelial cells and macrophages. Moreover, blocking these receptors alleviates the atherosclerosis that is induced by a high-fat diet or aggravated by chronic kidney disease (CKD) in mice. “These findings establish a mechanistic framework for the pro-atherogenic effects of ceramides and uncover therapeutic opportunities targeting ceramide signalling, offering innovative strategies beyond conventional lipid-lowering approaches,” highlights Wei Kong, lead investigator of the study.

Mount Sinai Cardiologists Present Late Breaking Trials and Breakthrough Studies at American College of Cardiology Scientific Sessions (ACC.25)

2025-03-26 - 2025-03

Top experts from Mount Sinai Fuster Heart Hospital in New York City will present late breaking trials and other landmark studies at ACC.25 taking place March 29-31 in Chicago. I have included details on their notable presentations below. We have two late-breaking clinical trials, and research on AI as it relates to the field of cardiology care. Please let me know if need to coordinate interviews involving their work. Our experts are also available to comment on trending topics, and outside studies.

Webinar on Cardiology and Cardio Care

useful links

Latest News

Explosion’ of incretin therapy use among new developments in cardiology

The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

Gujarat cardiologists threaten strike from Apr 1-7 demanding better PMJAY compensation

Bayer Pharma to expand cardiology, women’s health portfolios with new drugs this year

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

Dr. Christopher Kramer is New American College of Cardiology President

How 2 new Miami Tech endeavors aim ‘to bring the heartbeat back’

GE HealthCare Introduces Measures to Improve Cardiac Care Pathway

Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling

Mount Sinai Cardiologists Present Late Breaking Trials and Breakthrough Studies at American College of Cardiology Scientific Sessions (ACC.25)

cardiocare@confmeets.net

support@confmeets.net

+44-7477-467410